汇禾医疗完成数亿元D轮融资，聚焦心血管介入医疗器械研发

Core Insights - Shanghai Huihe Medical Technology Co., Ltd. has completed a Series D financing round led by Taiping Medical Health Fund, with existing shareholder Suzhou Sherpa II Equity Investment Partnership also participating [1] Company Overview - Huihe Medical is a world-leading cardiovascular intervention platform company with independent innovation capabilities, focusing on the research, production, and commercialization of cardiovascular interventional medical devices [1] - The company has developed world-leading products in the fields of structural heart disease, vascular intervention, and intelligent intervention [1] Product Highlights - The core product, K-Clip® transcatheter tricuspid valve repair system, replicates classic surgical procedures and repairs tricuspid regurgitation through minimally invasive surgery [1] - The K-Clip® system received approval from the National Medical Products Administration (NMPA) in March 2025 and has already begun large-scale commercialization [1] Future Outlook - The chairman of Huihe Medical, Lin Lin, stated that the company will continue to innovate in the field of cardiovascular intervention, aiming to provide patients with safer and less invasive treatment options and to offer doctors more convenient and controllable surgical tools [1]